Fly News Breaks for June 3, 2019
Jun 3, 2019 | 07:12 EDT
H.C. Wainwright analyst Joseph Pantginis raised his price target for Iovance Biotherapeutics to $32 from $26 saying the company's TIL therapy-mediated anti-tumor effects validate further clinical and market development. Iovance's TIL products, LN-144 and LN-145, are continuing to deliver significant clinical promise in metastatic melanoma and metastatic cervical cancer, and investors are starting to recognize and reward it, Pantginis tells investors in a research note. He keeps a Buy rating on the shares.
News For IOVA From the Last 2 Days
There are no results for your query IOVA